We are live on ! Find out more

APMD

Apnimed Inc

APMD

Market cap $1.21B

29.00 USD

+0.89

3.17%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

29.00

0.00

0%

1 day

3.17%

5 days

9.52%

1 month

-8.83%

3 months

16%

6 months

16%

Year to date

16%

1 year

16%

5 years

16%

10 years

16%

About: Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 57.1%

Negative 0%

Apnimed: What We Know Heading Into The Feb PDUFA

Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust Phase 3 efficacy, clear differentiation from CPAP, and manageable safety, with an NDA under FDA review and a February 2027 PDUFA date. APMD's financials show a transition from R&D to pre-commercial buildout, with a strong cash position and multiple years of runway to support launch activities.

Apnimed: What We Know Heading Into The Feb PDUFA

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on August 31, 2026, the compensation committee of Apnimed's board of directors granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 428,428 shares of the Company's common stock under Apnimed's 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $26.85, which is equal to Apnimed's closing trading price on September 1, 2026. One-fourth of the shares underlying each of the employee's stock options will vest on the first anniversary of each employee's start date and in equal monthly installments thereafter for the next three years, subject to such employee's continued employment with the Company on such vesting dates.

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Proactive Investors

Apnimed shares surge on bullish BofA initiation

Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA).

Apnimed shares surge on bullish BofA initiation

24/7 Wall Street

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

Primary Markets Group July 2026 U.S. IPO Update

The U.S. IPO market cooled in July following the record-shattering June. The month saw seven new issuers raise $3.0 billion in proceeds, a significant slowdown from the 19 deals and $97.9 billion priced in June that was skewed by the unprecedented SpaceX IPO. Looking at the six-month IPO backlog, 10 new issuers filed in July, bringing the total pipeline to 75 companies seeking to raise $3.2 billion in aggregate proceeds.

Primary Markets Group July 2026 U.S. IPO Update

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share.

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

See News Rankings

Price charts implemented using Lightweight Charts™